Follow us on Twitter
twitter icon@FreshPatents


Immunotherapy patents

      

This page is updated frequently with new Immunotherapy-related patent applications.




new patent Lym-1 and lym-2 targeted car cell immunotherapy
Car cells targeting and antibodies human hla-dr are described as a new method of cancer treatment. It is proposed that hla-dr car cells are safe and effective in patients and can be used to treat human tumors expressing the hla-dr..

new patent Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
Provided are novel human-derived antibodies specific for transthyretin (ttr), preferably capable of binding misfolded, misassembled, and/or aggregated ttr species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with ttr amyloidosis are provided.
Neurimmune Holding Ag


new patent Mimotopes for use in immunotherapy for shellfish and/or arthropod allergy
The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin met e 1.
The Chinese University Of Hong Kong


new patent Novel immunotherapy against several tumors including neuronal and brain tumors
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


new patent Radio-imaging and radio-therapy of cancer using antibodies to haah
The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-haah antibodies for tumor imaging and immunotherapy are provided..
Panacea Pharmaceuticals Inc.


Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
This invention relates to ly6g6f, vsig10, tmem25 and lsr proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble ly6g6f, vsig10, tmem25 and lsr molecules, extracellular domains of ly6g6f, vsig10, tmem25 and lsr and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Compugen Ltd.


Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
This invention relates to vstm5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.. .
Compugen Ltd.


Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Granulysin in immunotherapy
Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kd granulysin thereby producing a monocyte-derived dendritic cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
Oncomed Pharmaceuticals, Inc.

Sirp polypeptide compositions and methods of use

Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Antigen-specific immunotherapy using tolerizing liposomes

The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh

Liposome-based immunotherapy

The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats

Method and means for diagnosing and treating allergy

Disclosed is a method for diagnosing allergy in a human or animal patient, wherein the level of species-specific lipocalin, especially lipocalin 2 in a human patient, is measured in a sample of said patient and wherein a lowered level of said lipocalin compared to the level of said lipocalin in the corresponding sample of a human or animal that has no allergy, is indicative of an allergy, as well as a kit for performing this method, and a kit for quality control of allergen molecules or extracts used for immunotherapy of allergy by determining its siderophore-iron ligand load and thus immunomodulatory potency. Further, lipocalin proteins for use in treatment or prevention of allergies are provided, preferably complexed with siderophore-iron ligands..
Biomedical International R+d Gmbh

Chimeric antigen receptor compositions

Provided herein are compositions which exhibit novel diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope).
City Of Hope

Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use

Adoptive immunotherapy using t cells genetically redirected via expression of chimeric antigen receptors (cars) is a promising approach for cancer treatment. However, this immunotherapy is dependent in part on the optimal molecular design of the car, which involves an extracellular ligand-binding domain connected to an intracellular signaling domain by spacer and/or transmembrane sequences..

Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish

The present invention relates to a new generation of chimeric antigen receptors (car), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a vnar polypeptide derived from monomeric antibodies from cartilaginous fish. Such cars, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells.
Cellectis

Improved cell compositions and methods for cancer therapy

Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved t cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies.
Hadasit Medical Research Services And Development Ltd.

Compositions and methods of identifying tumor specific neoantigens

The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses..
The General Hospital Corporation

Methods and devices for allergy testing and treatment

A method of testing a patient for allergies includes obtaining from the patient a blood sample having an original volume of at most 0.5 ml, and testing the blood sample for ige reactive with antigens from a plurality of allergen sources by multiple elisa. The blood sample may be taken from the patient in a clinic, and/or the blood sample may be taken by a physician without venipuncture.
Spiriplex, Inc

Determinants of cancer response to immunotherapy

Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy. The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy can be predicted.
Memorial Sloan Kettering Cancer Center

Compounds and compositions for immunotherapy

Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer.
Shanghai Birdie Biotech, Inc.

Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), and a carrier protein, wherein the cp is selected from the group consisting of serotypes ia, ib, ii, iii, iv, v, vi, vii, viii, and ix, and wherein the cp has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates.
Pfizer Inc.

Novel msln targeting dna vaccine for cancer immunotherapy

The present invention relates to an attenuated mutant strain of salmonella comprising a recombinant dna molecule encoding mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of salmonella in cancer immunotherapy..
Vaximm Gmbh Mafinex-technologiezentrum

Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy

The present invention relates to use of cbp/ep300 bromodomain inhibitors for the treatment of cancer.. .
Constellation Pharmaceuticals, Inc.

Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon

Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (vlp) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class ii major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the vlp does not contain an alphavirus structural protein gene.. .
The United States Of America, As Represented By The Secretary, Dep. Of Health And Human Services

Novel promiscuous hpv16-derived t helper epitopes for immunotherapy

The present invention relates to novel amino acid sequences of peptides derived from hpv16 that are able to bind to mhc complexes of class ii, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and t-cells, based on said epitopes..
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts

Topk peptides and vaccines including the same

The present invention provides isolated epitope peptides derived from topk and immunogenic fragments thereof have an ability to induce cytotoxic t lymphocytes (ctls) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a topk-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have ctl inducibility.
Oncotherapy Science, Inc.

Id-protein targeted tumor cell vaccine

Id protein targeted cancer immunotherapy. The invention provides a cell-based attenuated live tumor cell vaccine that safely produces broad cellular tumor-specific immunity, protects against tumor formation in prophylactic tumor models, and in combination with the clinically relevant immune modulator s such as antibodies to ctla-4 or antibodies to pd-l1 can destroy established tumors in mammals..
Children's National Medical Center

Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same

Embodiments of the disclosure include methods and compositions for producing nkt cells effective for immunotherapy and also methods and compositions for providing an effective amount of nkt cells to an individual in need of immunotherapy. In specific embodiments, the nkt cells are cd62l+ and have been exposed to one or more costimulatory agents to maintain cd62l expression.
Baylor College Of Medicine

Combination of immunotherapy with local chemotherapy for the treatment of malignancies

The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer..
The Johns Hopkins University

Immunotherapy of cancer

Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune suppression mechanism.. .
Mirimmune Inc.

Silicon dioxide nanoparticles and the use thereof for vaccination

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer.
Merck Patent Gmbh

Method of immunotherapy for treatment of human papillomavirus infection

A method of treating human papillomavirus (hpv), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with hpv, and inducing an immune response to hpv. A method of overcoming hpv-induced immune suppression of langerhans cells (lc), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with hpv, and activating lc.
Irx Therapeutics, Inc.

Modular particles for immunotherapy

Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle.
Yale University

Enhanced generation of cytotoxic t lymphocytes by il-21 mediated foxp3 suppression

A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic t lymphocytes (ctl) preparation in a treatment-effective amount is described. In the method, the ctl preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate ctl population, the ctl population: (i) depleted of foxp3+ t lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of foxp3+ t lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21.
The Fred Hutchinson Cancer Research Center

Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or pi3k inhibitors, with antibodies or immunoconjugates against hla-dr or trop-2. Where immunoconjugates are used, they preferably incorporate sn-38 or pro-2pdox.
Immunomedics, Inc.

Composition and methods of genome editing of b-cells

The present invention provides methods compositions and methods of preparing autologous (or allogeneic) b cells that secrete a monoclonal of interest useful in immunotherapy or b cells with an altered function.. .
Dana-farber Cancer Institute, Inc.

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Apparatus and infusing an immunotherapy agent to a solid tumor for treatment

An immunotherapy delivery device is provided including a catheter and a pressure modulating device fixed adjacent the distal end of the catheter. In accord with aspects of the device, the lumen of the catheter is coated to facilitate delivery of a healthy immunotherapy agent.
Surefire Medical, Inc.

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods for identifying modulators of il-24 mediated apoptosis and immunotherapy

A method for identifying modulators of interleukin 24 (il-24) mediated apoptosis is disclosed. For il-24 apoptosis to be effective, the cells should express sigma 1 receptor (sir).
Research Foundation Of The City University Of New York



Immunotherapy topics:
  • Immunotherapy
  • Therapeutics
  • Antibodies
  • Immune Response
  • Monoclonal
  • Monoclonal Antibody
  • Stimulator
  • Immunostimulator
  • Compatibility
  • Histocompatibility
  • Specificity
  • Major Histocompatibility Complex
  • Radiation Therapy
  • Treatments
  • Amino Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9885

    file did exist - 2546

    1 - 1 - 51